The effectiveness of administration of grycopyrrolate 5 and 10 fig kg' and atropine 10 and 20 fig kg' 1 i.v. immediately before the induction of anaesthesia, to prevent arrhythmia and bradycardia following repeated doses of suxamethonium in children, was studied. A control group was included for comparison with the lower dote range of grycopyrrolate and atropine. A frequency of bradycardia of 50% was noted in the control group, but this was not significantly different from the frequency with the active drugs. Bradycardia (defined as a decrease in heart rate to less than 50 beat min~') was prevented when the larger dose of either active drug was used. It is recommended that either glycopyrrolate lOfigkg" 1 or atropine 20 MS kg" 1 i.v. should immediately precede induction of anaesthesia, in children, if the repeated administration of suzamethonhim is anticipated.
Bradycardia may follow repeated i.v. injections of suxamethonium (Savarese, 1981) . The mechanism appears to involve stimulation of cardiac parasympathetic postsynaptic receptors in a fashion analagous to that of acetylcholine, and this may lead to sinus arrest (McLeskey et al., 1978) . Although Martin (1958) reported that this effect could be decreased by the administration of atropine as a premedicant, it is disputed whether premedication with atropine or glycopyrrolate i.m. can prevent bradycardia following repeated doses of suxamethonium (Cozanitis et al., 1982) . Indeed, the efficacy of atropine i.v. in preventing the bradycardia caused by repeated doses of suxamethonium has been questioned (Cozanitis, Dundee and Khan, 1980) . Suxamethonium-induced bradycardia is more likely in sympathotonic individuals, such as children (Craythorne, Turndoff and Dripps, 1960; Leigh, McCoy and Belton, 1957) and although glycopyrrolate i.v. has been compared with atropine in children who required suxamethonium to facilitate intubation (Lavis, Lunn and Rosen, 1980) , no controlled trial has been carried out to compare these two drugs following the repeated administration of suxamethonium.
PATIENTS AND METHODS
The trial was divided into two stages: 
Stage 1
Twenty-six children younger than 14yr, about to undergo oesophagoscopy, duodenoscopy and injection of oesophageal varices were weighed, and premedicated with diazepam 0.2 mgkg" 1 orally 2 h before surgery. On arrival in the anaesthetic room, each child was connected to a portable electrocardiogram (ECG) with ratemeter and printout, and control measurements obtained.
The drug solutions were glycopyrrolate 0.2 ing ml" 1 , atropine O^mgml" 1 and normal saline. These were administered i.v. on a doubleblind basis following randomization in a volume of 0.025 ml kg" 1 , equivalent to glycopyrrolate 5 ng kg" 1 , atropine lOjigkg" 1 or saline (control). The effect on heart rate was observed for 3 min, and was followed by the induction of anaesthesia with thiopentone 5 mgkg" 1 . Suxamethonium 2mgkg~1 was given to facilitate tracheal intubation. In a few patients who received halothane for the induction of anaesthesia, the test drug was administered at least 1 rnin before the injection of suxamethonium. Anaesthesia was maintained with nitrous oxide and 0.5% halothane in oxygen with controlled ventilation. Arterial pressure was measured automatically (Dinamap, Critikon Inc. Tampa, Florida, U.S.A.) at 1-min intervals throughout the procedure.
Repeated doses of suxamethonium 0.5 nig kg" 1 were given on the first return of muscle twitch as monitored by a peripheral nerve stimulator (Ministim, Professional Instruments Co., Houston, Texas, U.S.A.) using the ulnar nerve at the wrist. The heart rate was recorded at 1-min intervals during the procedure, particular note being made of any bradycardia following the suxamethonium. If the rate decreased to less than 50 beatmin" 1 , the code was broken and appropriate treatment instituted. All arrhythmias were recorded.
Stage 2
The control group was eliminated following Stage 1, and the volume of the active preparations was doubled. The patients thus received 0.05 ml kg" 1 of drug, equivalent to glycopyrrolate lOngkg" 1 or atropine 20 ngkg" 1 ; otherwise, the test procedure was as outlined above.
RESULTS

Stage 1
Of the 26 patients, 10 received glycopyrrolate, 10 atropine and six saline (control). Some details of the patients studied are shown in table I. There were no statistically significant differences between the groups.
The frequency of arrhythmia and bradycardia observed in Stage 1 is shown in table II. There was no statistically significant difference in the occurrence of bradycardia between the two "treated" groups and the control group (Fisher's exact test).
Stage 2
Twenty-three patients were studied, of whom 14 received atropine and nine glycopyrrolate. Details of the patients in Stage 2 are shown in table III. There were no statistically significant differences between the groups.
The results in table IV show that the frequency of arrhythmias and bradycardia was decreased substantially by the larger dose of the two anticholinergic drugs. Only one episode of arrhythmia was noted (following atropine), and bradycardia did not occur in any patient.
The effect of glycopyrrolate and atropine on increasing the heart rate before the administration of the first dose of suxamethonium was also calculated from the results during both stages (table V). There were no statistically significant differences between the two drugs when compared at either dose range. Thus, the larger dose of either drug did not cause a significantly greater increase in heart rate than the smaller dose. At both doses, atropine caused a significant increase in heart rate over the control group, whereas with glycopyrrolate this was only so with the higher dose.
DISCUSSION
The emphasis in this study was to prevent significant bradycardia-arrhythmias in all patients following the repeated administration of suxamethonium. It should be noted that some studies were carried out before surgery (Cozanitis et al., 1982) . Thus, in the present study, less emphasis was placed on the difference in the decreases in heart rate with repeated doses of suxamethonium following the active drugs, than on the actual prevention of bradycardia. gests that all patients should receive anticholinergic drugs i.v. before the repeated administration of suxamethonium. When the smaller dose of anticholinergic was used, it was noted that a modest slowing of the heart rate following, say, the third dose of suxamethonium, would often lead to a more severe decrease after subsequent doses. There was no evidence of tachyphylaxis to repeated doses as has been reported in some studies (Graf, Strom and Wahlin, 1963). One might ask why a non-depolarizing agent was not used. In this study of 49 patients, 10 received two doses of suxamethonium or fewer. Thus, from Hinirai experience, it was considered that 20% of patients would have a duration of operation of less than lOmin, too short for easy reversal from nondepolarizing blockade. Initial experience with atracurium does not suggest this agent to be any better in this respect.
The use of pre-suxamethonium blockade with a small dose (less than one-quarter of the full relaxing dose) of a non-depolarizing neuromuscular blocking drug is said to prevent bradycardia following a second dose of suxamethonium ( of glycopyrrolate or 20^gkg~' of atropine. Both drugs were equally effective, and increasing the dose to this level did not cause excessive tachycardia. Since this study was completed, a further 50 patients have been studied using glycopyrrolate 10 ng kg"' in the manner described. No instance of bradycardia has been observed. Unfortunately, although glycopyrrolate i.v. is twice as potent as atropine on a weight per kilogram basis in anaesthetized patients (Mirakhur, Jones and Dundee, 1980) , the commercial preparation of atropine in the U.K. is three times the concentration (unlike the strength used in this study). This makes dose calculation more difficult with atropine, and theoretical considerations also suggest that the quaternary ammonium compound, glycopyrrolate, may be preferable because of lack of CNS effects. Hunsley, Bush and Jones (1982) noted central effects in children following administration of smaller doses of atropine than tlie maximum dose used in this study. However, in this study, no important side-effects were noted with either drug in the period after operation. 10 y 20 fig kg' 1 de atropina i.v. inmediatamente antes de la induccion de nni*nTiitin con el objeto de prevenir las arritmias y la bradicardia a raiz de dosis repetidas de suzametonio en ninos. Se inchiyo a un grupo de control con miras a compararlo con la gama mas baja de dosis de glicopirrolato y de atropina. Se observo una frccuencia del 50% de bradicardia en el grupo de control, pero no diieria de manera signifkante de la frecuencia observada con las substancias activat. Se previno la bradicardia (definida como un descenso del ritmo cardiaco a menos de 50 latidot tnin" 1 ) cuando se uso la dosis mayor de cualquiera de las substancias activas. Se rccomienda que se administre ya sea 10/igkg" 1 de glicopirrolato ya sea 20ngkg~' de atropina i.v. inmediatamente antes de la induccion de la anestesia en ninos si se contempla la administracion repetida de suxametonio.
